Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Ezoulin MJ et al. | Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment. | 2006 | Toxicol In Vitro | pmid:16472967 |
Isobe J and Mizuno A | Aspects of PAF (platelet activating factor)-induced aggregation by using rabbit platelets. | 1982 | Tokushima J. Exp. Med. | pmid:7170716 |
Inoue Y et al. | Effect of a platelet activating factor antagonist and antithrombin III on septicemia and endotoxemia in rats. | 1991 | Tohoku J. Exp. Med. | pmid:2063402 |
Nishihira J et al. | Purification and characterization of the specific binding protein for platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) from human platelets. | 1985 | Tohoku J. Exp. Med. | pmid:3001971 |
Ou MC et al. | Potential etiologic role of PAF in two major septic complications; disseminated intravascular coagulation and multiple organ failure. | 1994 | Thromb. Res. | pmid:8191415 |
Le Blanc K et al. | Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. | 1998 | Thromb. Res. | pmid:9772010 |
Eche N et al. | Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). | 1986 | Thromb. Res. | pmid:3726808 |
Chang GT et al. | Purification and characterization of a new anticoagulant protein, PP27, from placenta. | 2005 | Thromb. Res. | pmid:16122555 |
Alam I et al. | Human and rabbit platelets form platelet-activating factor in response to calcium ionophore. | 1983 | Thromb. Res. | pmid:6407140 |
Simon MF et al. | Effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether), on calcium movements and phosphatidic acid production induced by PAF-acether in human platelets. | 1987 | Thromb. Res. | pmid:3576518 |
Bochkov VN et al. | LDL- and agonist-induced Ca(2+)-mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II. | 1991 | Thromb. Res. | pmid:2063348 |
Bush LR and Smith SG | Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists. | 1986 | Thromb. Res. | pmid:2948294 |
Alam I and Silver MJ | Metabolism of 1-alkyl-2-acyl-GPC in human platelets in response to stimulation by thrombin. | 1987 | Thromb. Res. | pmid:3576519 |
Filep JG et al. | C-reactive protein inhibits binding of platelet-activating factor to human platelets. | 1991 | Thromb. Res. | pmid:2063349 |
Slattery CW and Beaumont DO | Sheep platelets as a model for human platelets: evidence for specific PAF (platelet activating factor) receptors. | 1989 | Thromb. Res. | pmid:2554526 |
Belch JJ et al. | Whole blood white cell aggregation: a novel technique. | 1987 | Thromb. Res. | pmid:2448894 |
Ostermann G et al. | Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. | 1983 | Thromb. Res. | pmid:6408754 |
Liu X et al. | Ginkgolide B inhibits platelet release by blocking Syk and p38 MAPK phosphorylation in thrombin-stimulated platelets. | 2014 | Thromb. Res. | pmid:25223809 |
Nguyên P et al. | Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. | 1995 | Thromb. Res. | pmid:7778064 |
Vargaftig BB et al. | Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. | 1982 | Thromb. Res. | pmid:7164036 |
Namm DH and High JA | Thrombin-induced formation of a polar lipid material within platelets that possesses platelet-activating activity. | 1980 | Thromb. Res. | pmid:7209881 |
Hanss M and Dechavanne M | 48740 RP, an antagonist of PAF, does not affect human plasma fibrinolysis before and after venous occlusion. | 1988 | Thromb. Res. | pmid:3126559 |
Okamoto M et al. | Platelet activating factor (PAF) involvement in endotoxin-induced thrombocytopenia in rabbits: studies with FR-900452, a specific inhibitor of PAF. | 1986 | Thromb. Res. | pmid:3754990 |
Bretschneider E et al. | ADP-, PAF- and adrenaline-induced platelet aggregation and thromboxane formation are not affected by a thromboxane receptor antagonist at physiological external Ca++ concentrations. | 1994 | Thromb. Res. | pmid:7992234 |
Sturk A et al. | Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway. | 1985 | Thromb. Res. | pmid:2934863 |
Jones KP et al. | Salivary PAF in acute myocardial infarction and angina: changes during hospital treatment and relationship to cardiac enzymes. | 1994 | Thromb. Res. | pmid:7992251 |
Juhan-Vague I et al. | Possible participation of adenosine 5'-diphosphate, arachidonic acid and paf-acether in the platelet pro-aggregating effect of uncontrolled insulin-dependent diabetic erythrocytes in vitro. | 1985 | Thromb. Res. | pmid:3923649 |
Shukla SD et al. | Hypersensitivity of diabetic human platelets to platelet activating factor. | 1992 | Thromb. Res. | pmid:1329254 |
Tsien WH et al. | Variable responses of human platelets to synthetic platelet activating factor and their modification by epinephrine. | 1982 | Thromb. Res. | pmid:7164038 |
Kurose I et al. | Involvement of superoxide anion and platelet-activating factor in increased tissue-type plasminogen activator during rat gastric microvascular damages. | 1991 | Thromb. Res. | pmid:1650966 |
Westwick J et al. | Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. | 1986 | Thromb. Res. | pmid:3715810 |
Valone FH | Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers. | 1987 | Thromb. Res. | pmid:3590086 |
Tokumura A et al. | Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists. | 1987 | Thromb. Res. | pmid:3590110 |
Ishii H et al. | Thiolprotease inhibitor, EST, can inhibit thrombin-induced platelet activation. | 1990 | Thromb. Res. | pmid:2382255 |
Tokumura A et al. | Platelet aggregation induced by ether-linked phospholipids. 1. Inhibitory actions of bovine serum albumin and structural analogues of platelet activating factor. | 1987 | Thromb. Res. | pmid:3647677 |
Wade PJ et al. | Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets. | 1986 | Thromb. Res. | pmid:3961730 |
Karlsson H et al. | Heparin ameliorates pulmonary hypertension induced by platelet-activating factor in pigs. | 1998 | Thromb. Res. | pmid:9694244 |
Hofmann B et al. | Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets. | 1988 | Thromb. Res. | pmid:3381200 |
Cox CP and Wood KL | Selective antagonism of platelet-activating factor (PAF)-induced aggregation and secretion in washed rabbit platelets by CV-3988, L-652731, triazolam and alprazolam. | 1987 | Thromb. Res. | pmid:3629553 |
Catalán RE et al. | Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. | 1994 | Thromb. Res. | pmid:7974386 |
Ostermann G et al. | Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. | 1987 | Thromb. Res. | pmid:3629555 |
Davis RB and Johnson MF | Effects of bacterial endotoxin and platelet activating factor (PAF) on human platelet aggregation in native whole blood. | 1986 | Thromb. Res. | pmid:3544327 |
Nishizawa EE and Della-Coletta AA | The formation of a thrombin-like material (TLM) following stimulation of leukocytes. | 1984 | Thromb. Res. | pmid:6484896 |
Heinrich J and Zimmermann RE | Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. | 1984 | Thromb. Res. | pmid:6523451 |
Glusa E et al. | Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. | 1989 | Thromb. Res. | pmid:2528843 |
Stahl GL et al. | Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock. | 1989 | Thromb. Res. | pmid:2718150 |
Hwang SB et al. | Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. | 1984 | Thromb. Res. | pmid:6429890 |
Sloan IG and Firkin BG | Impaired fibrinolysis in patients with thrombotic or haemostatic defects. | 1989 | Thromb. Res. | pmid:2814943 |
Skeaff CM and Holub BJ | The effect of fish oil consumption on platelet aggregation responses in washed human platelet suspensions. | 1988 | Thromb. Res. | pmid:3187952 |
Griffin KJ and Levy JV | The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF). | 1988 | Thromb. Res. | pmid:3187959 |
Ostermann G et al. | Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets. | 1984 | Thromb. Res. | pmid:6710440 |
Petty AC and Scrutton MC | Platelet aggregation in whole blood: is the response to adrenaline, 5-hydroxytryptamine and PAF a direct consequence of stimulation by these agonists? | 1989 | Thromb. Res. | pmid:2749609 |
Beaumont DO et al. | Measuring platelet function with platelet shape change, an early event in aggregation. | 1989 | Thromb. Res. | pmid:2646752 |
Janero DR et al. | Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. | 1988 | Thromb. Res. | pmid:3413730 |
Suttorp N et al. | Stimulation of PAF-synthesis in pulmonary artery endothelial cells by Staphylococcus aureus alpha-toxin. | 1992 | Thromb. Res. | pmid:1440526 |
Moon DG et al. | Platelet activating factor and sheep platelets: a sensitive new bioassay. | 1990 | Thromb. Res. | pmid:2326773 |
Violi F et al. | Human platelet aggregation by PAF and thromboxane production. | 1987 | Thromb. Res. | pmid:3424290 |
Benveniste J et al. | Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. | 1982 | Thromb. Res. | pmid:6803388 |
Seth P et al. | Effect of platelet activating factor antagonists in different models of thrombosis. | 1994 | Thromb. Res. | pmid:7900097 |
Klöcking HP et al. | Release of tissue-type plasminogen activator by platelet-activating factor. | 1985 | Thromb. Res. | pmid:4040278 |
Pletscher A et al. | LDL induced shape change reaction of platelets is not due to PAF. | 1989 | Thromb. Res. | pmid:2609294 |
Cox CP | Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. | 1986 | Thromb. Res. | pmid:2421432 |
Nunn B | Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. | 1983 | Thromb. Res. | pmid:6648898 |
Croft KD and Beilin LJ | Platelet and neutrophil function and eicosanoid release in a subject with abetalipoproteinaemia. | 1993 | Thromb. Res. | pmid:8385810 |
Vrzheshch PV et al. | Cell response kinetics: the phenomenon of supercooperativity in aggregation of human platelets. | 1992 | Thromb. Res. | pmid:1523610 |
Teng CM et al. | Antiplatelet actions of some coumarin compounds isolated from plant sources. | 1992 | Thromb. Res. | pmid:1523611 |
Chlopicki S et al. | Obligatory role of lipid mediators in platelet-neutrophil adhesion. | 2003 | Thromb. Res. | pmid:14592550 |
Kawamura M et al. | Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation. | 1993 | Thromb. Res. | pmid:8332959 |
Joseph R et al. | Platelet-activating factor and red blood cells. | 1989 | Thromb. Res. | pmid:2734734 |
Kohayakawa M and Inoue K | Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. | 1986 | Thromb. Res. | pmid:3083530 |
Ostermann G et al. | The role of lipoproteins in the degradation of platelet-activating factor. | 1986 | Thromb. Res. | pmid:3798402 |
Stormorken H et al. | A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). | 1983 | Thromb. Res. | pmid:6857589 |
Kloprogge E et al. | Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. | 1983 | Thromb. Res. | pmid:6857605 |
Battistini B et al. | Endothelin-1 does not affect human platelet aggregation in whole blood and platelet rich plasma. | 1990 | Thromb. Res. | pmid:2278035 |
Ostermann G et al. | Inhibition of PAF-induced human platelet responses by newly synthesized ether phospholipids. | 1991 | Thromb. Res. | pmid:2028445 |
Joseph R et al. | Endothelin-1 and human platelet activity. | 1991 | Thromb. Res. | pmid:2028454 |
Tencé M et al. | Ether-phospholipid composition in neutrophils and platelets. | 1985 | Thromb. Res. | pmid:4024039 |
Hadváry P and Baumgartner HR | Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor. | 1983 | Thromb. Res. | pmid:6868019 |
Leoncini G et al. | Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. | 1997 | Thromb. Res. | pmid:9175236 |
Tan EL and Snyder F | Metabolism of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by capillary endothelial cells isolated from rat epididymal adipose tissue. | 1985 | Thromb. Res. | pmid:4024051 |
Despotis GJ et al. | Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood. | 1997 | Thromb. Res. | pmid:9175242 |
Hayashi M et al. | Detection of platelet-activating factor in exudates of rats with phorbol myristate acetate-induced pleurisy. | 1987 | Thromb. Res. | pmid:3433255 |
Ding YA et al. | Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound. | 1995 | Thromb. Res. | pmid:7740521 |
Garcia JG et al. | Effect of platelet activating factor on leukocyte-endothelial cell interactions. | 1988 | Thromb. Res. | pmid:2842887 |
Bussolino F et al. | Intravascular release of platelet activating factor in children with sepsis. | 1987 | Thromb. Res. | pmid:3441909 |
Suzuki K et al. | The influence of 2-mercaptoethanol on von Willebrand factor and bovine platelet aggregating factor. | 1980 Feb 1-15 | Thromb. Res. | pmid:6966083 |
Küster LJ and Frölich JC | PAF-induced platelet aggregation and TXB2 formation. | 1989 | Thromb. Res. | pmid:2922704 |
Ostermann G et al. | Stimulation and desensitization of human and rabbit platelets by 1-O-hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine and analogues. | 1986 | Thromb. Res. | pmid:3764811 |
Ishii H et al. | A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. | 1982 | Thromb. Res. | pmid:6897588 |
Neiman J et al. | Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. | 1989 | Thromb. Res. | pmid:2617478 |
Pfliegler G et al. | Sodium fluoride induced activation of phospholipase C in intact human platelets does not depend on ADP, PAF or arachidonate products. | 1993 | Thromb. Res. | pmid:8503122 |
Altman R et al. | Why single daily dose of aspirin may not prevent platelet aggregation. | 1988 | Thromb. Res. | pmid:3140408 |
Lukaszyk A et al. | Does acute experimental pancreatitis affect blood platelet function? | 1989 | Thromb. Res. | pmid:2524119 |
Lecompte T et al. | Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP. | 1990 | Thromb. Res. | pmid:2117306 |
McGowan EB and Detwiler TC | Characterization of the thrombin-induced desensitization of platelet activation by thrombin. | 1983 | Thromb. Res. | pmid:6356458 |
Mabilat-Pragnon C et al. | Urokinase localization and activity in isolated eosinophils. | 1997 | Thromb. Res. | pmid:9526961 |
Csáki C et al. | Role of platelet-activating factor in the development of endothelial dysfunction in hemorrhagic hypotension and retransfusion. | 1992 | Thromb. Res. | pmid:1412179 |
May JA et al. | Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. | 1997 | Thromb. Res. | pmid:9361371 |
Patterson WR et al. | Aggregation of killer whale platelets. | 1993 | Thromb. Res. | pmid:8327987 |
Lian EC et al. | Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. | 1984 | Thromb. Res. | pmid:6420930 |